A 2026 buyer guide to AI diagnostics in longevity clinics: real use cases, red flags, physician oversight, FDA caveats, and questions before you pay.
A buyer guide to longevity clinic blood panels: which biomarkers change decisions, which are exploratory, and what red flags to avoid before paying.
A patient-safety guide to serious longevity clinic standards in 2026: core measurements, AI diagnostics, biomarkers, biological-age limits, and safeguard questions.
This weekly WLC intelligence digest covers serious clinic standards, AI diagnostics, GLP-1 programs, full-body MRI, biological-age testing, and peptides.
A May 2026 intelligence digest on longevity clinic trends: AI diagnostics, GLP-1s, biomarkers, imaging, and which clinic models deserve buyer trust.
This week's radar covers blood-based Alzheimer's biomarkers, FDA-cleared imaging AI, DXA/DEXA upgrades, wearable VO₂ estimates, and smarter questions for buyers.
A practical buyer’s guide to longevity health assessments: biomarkers, imaging, genetics, fitness testing, costs, and the questions to ask before booking.
Human Longevity Inc. partners with LEV Foundation to study blood from centenarians and supercentenarians using multi-omic analysis — seeking biomarkers that explain why some people age far more slowly.
The U.S. government's ARPA-H launches the PROSPR program: $144M over five years to identify early aging biomarkers and run the first clinical trials explicitly aimed at extending healthy lifespan.